Amylyx reported Phase 3 success for avexitide, a GLP-1 receptor antagonist intended for post-bariatric hypoglycemia (PBH), showing a substantial reduction in serious hypoglycemic events versus placebo. The company framed the results as pivotal and said the win supports a path toward FDA submission and potential first-in-class use for PBH. The program adds urgency because PBH remains a difficult-to-treat endocrine condition after Roux-en-Y and other bariatric surgeries, where management options can be limited and frequent monitoring is typical. Analysts will likely focus on effect size consistency, safety signals, and how the trial’s clinical endpoints map onto regulator expectations. With the Phase 3 outcome, attention shifts to operational readiness for launch if approved, including payer strategy and the clinical workflow for PBH screening and dosing. PBH could also become a bellwether for Amylyx’s broader attempt to re-center the company’s pipeline around endocrine therapeutics.